secwatch.observer — SEC 8-K summary
======================================

Issuer:     Compass Therapeutics, Inc. (CMPX)
CIK:        0001738021
Form:       8-K
Filed at:   2024-01-05T23:59:59+00:00
Accession:  0001171843-24-000082
Event type: leadership
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Compass Therapeutics: CEO change to Bisker-Leib, CTX-471 CR in SCLC, $152M cash
-------------------------------------------------------------------------------

- CEO succession: Vered Bisker-Leib appointed CEO effective Jan 9, 2024; Thomas Schuetz becomes President of R&D and Vice Chair.
- Year-end 2023 cash & securities ~$152M, providing runway into mid-2026.
- CTX-471: SCLC patient partial response converted to complete response; new PR in melanoma yields 27% ORR (3/11).
- CTX-009: COMPANION-003 top-line data expected mid-2024; COMPANION-002 top-line data in H2 2024.
- CTX-8371 IND accepted; first patient dosing expected in Q1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1738021/000117184324000082/0001171843-24-000082-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1738021/000117184324000082/f8k_010524.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-000082

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer